International Journal of Medical Sciences (IJMS)
Volume 2, Issue 2, July-December 2024, pp. 1–24, Article ID: IJMS_02_02_001
Available online at https://iaeme.com/Home/issue/IJMS?Volume=2&Issue=2
Journal ID: 1452-2145

CURRENT PROGRESS IN THERAPIES AND FUTURE DIRECTIONS ON THE DEVELOPMENT OF NOVEL DRUG DELIVERY SYSTEM FOR ENHANCED CANCER TREATMENT

Piyush Tiwari
Department of Pharmaceutics, Columbia Institute of Pharmacy,
Raipur, Chhattisgarh, 493111, India

Mahendra Kumar Sahu
Department of Pharmaceutical Quality Assurance, Columbia Institute of Pharmacy,
Raipur, Chhattisgarh, 493111, India

Rahul Kumar
Department of Pharmaceutical Chemistry, Columbia Institute of Pharmacy,
Raipur, Chhattisgarh, 493111, India

Swapnil Lal
Department of Biotechnology, Columbia Institute of Pharmacy, Raipur,
Chhattisgarh, 493111, India

Shailendra Kumar Sharma*
Department of Pharmaceutics, Columbia Institute of Pharmacy, Raipur,
Chhattisgarh, 493111, India

***Corresponding Author**

ABSTRACT

Cancer afflicts millions worldwide, presenting a complex challenge with current treatments like chemotherapy and radiation therapy, which, while effective, often induce severe side effects and harm healthy cells. Targeted drug delivery systems (DDS) offer a promising avenue for cancer treatment by delivering medications directly to cancer cells while sparing healthy tissue. This review provides an extensive summary of the state of the art in targeted drug delivery systems for cancer treatment, exploring their types, limitations, recent advancements, and future potential.

DDS has evolved significantly over recent decades, leveraging advancements in pharmacology and pharmacokinetics. Controlled drug release, pioneered in the 1950s, has revolutionized drug delivery by offering predetermined release rates and durations, thereby optimizing therapeutic efficacy. These systems exhibit prolonged lifespan, maintaining effectiveness over days to years, and provide precise control over drug release kinetics and spatial distribution. Moreover, they mitigate drug toxicity, enhance pharmacological activity, improve target site accumulation, and bolster patient compliance and acceptance.

Cancer, characterized by aberrant cell proliferation, necessitates multifaceted treatment approaches involving surgery, radiation, and chemotherapy. Chemotherapy, though widely used, poses challenges due to its systemic nature and non-specific targeting, resulting in collateral damage to healthy tissues. The significance of targeted drug delivery lies in its potential to enhance cancer treatment efficacy while minimizing adverse effects.

In conclusion, targeted drug delivery systems represent a pivotal advancement in cancer therapy, offering improved efficacy and reduced toxicity compared to conventional treatments.

Key words: Novel drug delivery system, Nano-medicine, Cancer, Anti-Cancer Drugs.

Cite this Article: Piyush Tiwari, Mahendra Kumar Sahu, Rahul Kumar, Swapnil Lal, Shailendra Kumar Sharma, Current Progress in Therapies and Future Directions on The Development of Novel Drug Delivery System for Enhanced Cancer Treatment, International Journal of Medical Sciences (IJMS), 2(2), 2024, pp. 1-24.
https://iaeme.com/Home/issue/IJMS?Volume=2&Issue=2

1. INTRODUCTION

Tumour ranks as the subsequent most prevalent cause of death worldwide. The incidence of tumour has generally intensified in the United States alone, there were about 1,665,540 individuals suffering from cancer in 2014, and 585,720 of them had died from the disease. Therefore, cancer is a major issue the impact everyone health in human civilization. Unfortunately, there are significant barriers to an accurate therapy since the illness is changeable at the cellular level. Cancer is the cause of advanced and deadly kinds of sickness. [1-3] Patients with cancer almost always have a minimal standard of life and a low chance of survival. Cancer cells react significantly to identical anti-cancer treatments in terms of responsiveness and responsibility since each cancer is unique, much as the numerous forms of cancer. Malignancy is encouraged by a series of gradually developing gene mutations that change how cells function. [4-6] It is clear that chemicals perform a part in the development of tumours and the changes that occur to genetic materials. Many chemicals that are harmful when smoked also contribute to lung malignancy. It's noteworthy to note that environmental pollutants that have the capacity to cause cancer may also induce genetic illnesses and gene mutations by directly as well as indirectly affecting the cytoplasm and nucleus of cells. Together, bacteria, viruses, and radiation contribute 7% of cancer cases and are considered additional carcinogenic factors. [7–12]

Most often, cancer causes critical genes to be lost and cellular connections to break down. The alteration impacts the cell phase and result in atypical proliferation of cell. When a genetic mutation occurs, proto-oncogenes which are very detrimental to a cell's capacity to survive transform into oncogenes, which typically regulate cell division and proliferation. [13–15] One such consequence of lack of tumour suppressor genes is uncontrollably large proliferation of cell.

Repair-related genetic material often encode proteins and/or enzymes; There are now over 30 distinct verities of restorative proteins know. Puracil removal from DNA fundamentally plays two functions in properly mending DNA: it prevents UV light-induced damage to genetic material and removes the original UV-induced DNA injury. [16–20] The cancer pathophysiology shown in Figure No. 1

Fig.1: - Pathophysiology of Cancer



2. NOVEL DRUG DELIVERY SYSTEM

The method a drug is given can have a big impact on how effective it is. There exists an optimal concentration range for certain drugs, beyond or below which there may be no therapeutic benefit; these concentrations may be hazard or have no effect at all. However, the necessity for a multimodal strategy to deliver medicine to targets inside tissues has grown as a result of the poor progress made in enhancing the effectiveness of treating critical illnesses. New hypotheses were therefore created about the regulation of drug kinetics, pharmacodynamics, indiscriminate toxicity, immunogenicity, accessibility, and drug effectiveness. These innovative techniques, dubbed "drug delivery systems" (DDS), are based on multidisciplinary methods that integrate the fields of molecular medicine, polymer science, and bio hybrid chemistry. Various drug distribution and concentration techniques are now being developed to decrease drug elimination and deterioration, prevent adverse effects, increase medicine accessibility, and increase the percentage of the medicine gathered in the required zone. [21-30]

Definition: A novel drug delivery system (NDDS) is a fresh strategy for supplying pharmaceutical chemicals in the body where they are needed to safely produce the intended pharmacological effects. It involves creative creation, formulations, new technology, and unique approaches. [31]

2.1 Characteristics of Novel Drug Delivery System [32-34]

- Boost the bioavailability.
- Provide regulated medication administration.
- Deliver the medication undamaged to the target location, avoiding healthy tissue.
- Maintaining stability and delivery under different physiological conditions.
- Simple to use, dependable, and safe.
- Economical.

2.2 Benefits of Novel Drug Delivery System [35-36]

- Medication: Suitable dosage, at the appropriate moment, and in a bright area.
- Industrial: Lower manufacturing costs and more effective utilization of pricey components.
- Social: Better therapy, higher standard of life, and benefits for patient's pathophysiology of cancer.

Cancer pathogenesis occurs in several phases. The first stage is called initiation, during which a mutation in a cell's DNA causes oncogenes genes that stimulate cell growth to become active, or tumor suppressor genes genes that limit cell growth to become inactive. During the second step, known as promotion, a small cluster of aberrant cells is formed by the mutant cells being supporting to divide and expand faster. The third stage, known as progression, is when the atypical cells continue splitting and expending until they develop a malignant that hass the ability to invade surrounding tissues and spread of the body via the circulatory or lymphatic pathways. The metabolic level of pathophysiology of cancer shown in figure no 2.

Fig.2: - Pathophysiology of cancer at Metabolic Level



3. OBJECTIVE OF DEVELOPMENT OF DRUG DELIVERY SYSTEM [37-50]

Developing Novel Drug Delivery Systems for Targeted Malignancy Therapy **-**In the treatment about cancer or cancer therapy, the crucial area of research and innovation is to develop such delivery system or dosage form of cancer medicine which can be able to target the cancer cells with minimum side effect or without effectively the patient's standard of living. So the goal is to developed such targeted cancer therapy by using advancement of drug deliver i.e. novel drug delivery system which could provide better & effective cancer treatment with minimum side effect.

- One of the greatest important areas of oncology research and innovation is the creation of innovative drug delivery systems for targeted cancer treatment. These systems aim to lessen the negative effects of cancer therapies while growing their efficacy. The following are some major goals and factors that are necessary for this project:
- Targeted Drug Delivery: Create carriers or nanoparticles that have the capacity to identify and attach to antigens or markers unique to cancer in order to create drug delivery systems that specifically target tumor cells while preserving healthy tissues.
- To guarantee that cancer medications stay effective throughout travel, it is important to improve their stability inside the delivery system.

- Design delivery devices that provide steady and regulated release of the medication to the tumor location. This may minimize systemic damage while optimizing medication exposure to cancer cells.
- Make sure the medication delivery mechanism is both safe and biocompatible before using it on people. Carry out thorough experiments to evaluate any possible harmful consequences.
- Personalization: Examine the potential for customizing medication delivery systems to each patient's unique profile, taking into account variables such as cancer stage, tumor kind, and genetics.
- Multimodal Therapy: Investigate the development of systems that can deliver multiple therapeutic agents simultaneously, such as chemotherapy drugs, immunotherapy, or gene therapies, to enhance treatment efficacy.
- Minimizing Resistance: Address the issue of drug resistance by developing delivery systems that can overcome or mitigate resistance mechanisms employed by cancer cells.
- Imaging and Monitoring: Incorporate imaging and monitoring components into the delivery system to track drug distribution and treatment response in real time.
- Biodegradability: Design delivery systems that are biodegradable and can be cleared from the body once the drug has been delivered, reducing long-term side effects.
- Scale-up and Manufacturing: Develop scalable manufacturing processes for these delivery systems to ensure their availability and affordability for widespread use.
- Regulatory Compliance: Ensure that the drug delivery systems meet regulatory standards and undergo rigorous testing for safety and efficacy before clinical use.
- Collaboration: Foster collaboration between researchers, clinicians, pharmaceutical companies, and regulatory bodies to streamline the development and approval process.
- Patient Access: Work towards making these advanced therapies accessible to a broader patient population, including addressing cost and infrastructure challenges.
- Clinical Trials: Conduct well-designed clinical trials to assess the effectiveness of these novel drug delivery systems in real-world settings.
- Education and Outreach: Educate healthcare providers, patients, and the public about the benefits and potential risks of targeted cancer therapies using these novel delivery systems.
- Ethical Considerations: Address ethical problems related to patient consent, data confidentiality, and the use of emerging technologies in cancer therapy.
- Continuous Innovation: Stay updated with the latest advancements in the field and continuously innovates to improve the effectiveness and safety of drug delivery systems for malignancy therapy.
- Targeted Drug Delivery: Design carriers or nanoparticles that can understant and bind to tumor-specific markers or antigens to develop drug delivery systems specifically targeting cancer cells while sparing healthy tissues.
- Enhanced Drug Stability: Improve the stability of cancer drugs within the delivery system to ensure that they remain effective during transport
- Controlled Release: Design delivery systems that allow for controlled and sustained drug release at the tumor site. This can optimize drug exposure to cancer cells while minimizing systemic toxicity.
- Biocompatibility and Safety: Ensure that the drug delivery system is biocompatible and safe for use in humans. Conduct rigorous testing to assess any potential toxic effects.

- Personalization: Explore the possibility of tailoring drug delivery systems to individual patient profiles, considering factors like genetics, tumor type, and stage of tumor.
- Multimodal Therapy: Investigate the growth of systems that may deliver multiple therapeutic agents simultaneously, such as chemotherapy drugs, immunotherapies or gene therapies, to enhance treatment efficacy.
- Minimizing Resistance: Address the issue of drug resistance by developing delivery systems that may overcome or mitigate resistance mechanisms employed by cancer cells.
- Imaging and Monitoring: Incorporate imaging and monitoring components into the delivery system to track drug distribution and treatment response in real time.
- Biodegradability: Design delivery systems that are biodegradable and can be cleared from the body once the drug has been delivered, reducing long-term side effects.
- Scale-up and Manufacturing: Develop scalable manufacturing processes for these delivery systems to ensure their availability and affordability for widespread use.
- Regulatory Compliance: Ensure that the drug delivery systems meet regulatory standards and undergo rigorous testing for safety and efficacy before clinical use.
- Encourage cooperation between researchers, physicians, pharmaceutical corporations, and regulators in order to expedite the process for growth and certification.
- Patient Access: Work towards making these advanced therapies accessible to a broader patient population, including addressing cost and infrastructure challenges.
- Clinical studies: To evaluate the efficacy of these innovative medication delivery methods in practical situations, conduct carefully planned clinical studies..
- Education and Outreach: Educate healthcare providers, patients, and the public about the benefits and potential risks of targeted cancer therapies using these novel delivery systems.
- Ethical Considerations: Address ethical problem related to patient consent, data confidentiality, and the use of emerging technologies in cancer therapy.
- Continuous Innovation: Stay updated with the latest advancements in the field and continuously innovates to progress the effectiveness and protection of drug delivery systems for cancer therapy.

It will need a multidisciplinary team with expertise in chemistry, pharmacology, nanotechnology, cancer, and other areas to accomplish these goals. Developing innovative methods for delivering drugs that might have a major inspiration on the results of tumor therapy requires cooperation and continuous research. [51]

4. HISTORY & DEVELOPMENT OF CANCER TREATMENT [52-62]

The history and development of cancer treatment shown in table no.1

Table 1: - History & Development of Cancer Treatment

Serial no	Year	Advancement
1.	1775	Squamous cell carcinoma and chimney soot
2.	1882	Management of breast cancer with the initial radical mastectomy
3.	1895	The first x-ray
4.	1899	The first instance of cancer treatment using radiation therapy
5.	1902	A single cell with chromosomal damage and a cancer tumour
6.	1911	Cancer in chickens
7.	1915	Cancer in rabbit
8.	1928	The pap smear
9.	1937	The national cancer institute (NCI)
10.	1941	Hormonal therapy
11.	1947	Anti-metabolites
12.	1949	Mustard with nitrogen
13.	1950	Smoking cigarettes and lung cancer
14.	1953	The first full cure a human solid tumour
15.	1958	chemotherapy in combination
16.	1971	The national cancer act
17.	1979	The TP53 gene
18.	1984	HER 2 gene discovered
19.	1985	Breast conserving surgery
20.	1986	HER2 oncogenes cloning
21.	1996	Anastrozole
22.	1997	Rituximab
23.	1998	Breast cancer prevention study funded by NCI
24.	2001	Imatinib mesylate
25.	2003	Prostate cancer prevention study (PCPT) funded by NCI
26.	2006	Temoxifen with raloxifene: an NCI trial (STAR)
27.	2009	Cervarix
28.	2010	The first vaccination for treating cancer in humans
29.	2010	Lung cancer screening study (NLST) sponsored by NCI
30.	2012	PLCO cancer screening trial funded by NCI
31.	2014	Analyzing DNA in cancer
32.	2014	Gardasil 9
33.	2016	Cancer moonshot
34.	2017	Pediatric MATCH
35.	2017	CAR T-cell therapy
36.	2017	Genomic profiling tests
37.	2018	TCGA pan cancer atlas
38.	2018`	NCI-sponsered TAILORx clinicle trial
39.	2018	Larotrectinib
40.	2020	worldwide full genome analysis of pancreatic cancer

5. RECENT CASE STUDY IN CANCER TREATMENT

- Prostate cancer incidence in India are predicted to treble by 2040, reaching 2.9 million cases yearly. Hazard features for the sickness include age, race, and family history, with lifestyle decisions influencing early signs. For early discovery and successful treatment, routine screening tests are essential. Prostate cancer makes up 15% of all incidences of cancer in males, which makes it a major worry at the moment.
- A Times of India story from April 7, 2024 states that women's lifestyle choices might increase their risk of breast and cervical cancer. This is because the quantity of tumor cases in India is on the rise, particularly among women. There is an immediate need for public health programs and awareness campaigns because of the problems caused by smoke, obesity, lack of screening, and sedentary lifestyles.
- The country's fatal illness epidemic now has a new name according to a recent health study. Indians' general health seems to be declining, according to a survey by Apollo Hospitals. The study, which was made public on April 7, World Health Day 2024, showed that 15.7 lac Indians would have cancer by 2025, up from the 14 lac who had the disease in 2020.

Treatment of Cancer

Considering the many types of cancer, there is an extensive selection of medicines available, and each kind of cancer requires a different kind of therapy. Numerous therapeutic options exist, such as hormone therapy, chemotherapy, chemotherapy, radiation therapy, surgery, small-molecule medicines or monoclonal antibodies for targeted therapy, and PARP inhibitors such as olaparib. Immunotherapy, treatment with photodynamic therapy, heat shock, and stem-cell therapy are other therapies. Several different medications, including chemotherapy, are used in the most common cancer treatment regimen, which is followed by surgery. Angiogenesis inhibitors are sometimes used to increase immunotherapy's advantages. [63]

The position, grade, and stages of the tumor, in addition to the patient's general condition, all affect the available treatment options. Biomarker testing may be used to determine which cancer type will respond best to a certain therapy. There are constantly new cancer experimental medicines being explored. Estimates from 2023 indicate that one in five persons will be identified with cancer at nearly time in their life. [64]

The major goals of tumor therapy are either to treatment the disease by eradicating it completely or to greatly extend the patient's life. Soothing treatment becomes important when the diagnosis is deprived and the cancer is thought to be fatal.

Different Treatment Types

For the many types of cancer, there is an extensive selection of medicines available, and each kind of cancer requires a different kind of therapy. It is possible to use hormone therapy, specific therapy, immunotherapy, chemotherapy, radiation therapy, and surgery among other treatments. The strategies for treating cancer have expanded along with our understanding of the essential biological processes. As far back as ancient Egypt, tumors could be removed surgically. In the late 1800s, radiation and hormonal treatment were developed. The 20th century saw the development of chemotherapy, immunotherapy, and targeted medications.

In order to proliferation efficiency, exactness, survival, and standard of life, managements will be established and adapted pursuant to new discoveries about the biology of cancer. [65–66] Figure No. 3 displays many cancer therapy choices.

Fig.3: -Various Options of Cancer Treatment

6.1. Surgery

If malignant tumors are totally removed surgically, they may recover. But if the cancer has expanded (metastasized) to other areas, it is usually not feasible to eradicate it entirely with surgery. Cancer starts locally, moves to the lymph nodes, and then spreads throughout the body, based on the Halstedian model. This has led to an increasing prevalence of locally limited therapy, such as surgery, for small cancers. More people are starting to recognize that even small, localized tumors may spread. A mastectomy and lumpectomy for breast cancer, a prostatectomy for prostate tumor, and cancer of the lungs surgery for cancers that are not small cells are a few instances of surgical procedures for cancer. The objective of surgery might be to remove the organ entirely, single a portion of the tumor, or both.

Operation is often essential for performance, which involves removing the primary tumor and determining if the disease has progressed to lymph nodes in the vicinity. Staging plays a key character in establishing diagnosis and whether adjuvant cure is required. Surgery may be essential to treat indications such as intestinal obstruction or looseness of the spinal cord. This kind of treatment is known as mollifying care. Surgical procedure may be performed both before and after obtaining further medical attention. Preoperative treatment is sometimes indicated with the term "neoadjuvant therapy." Neoadjuvant chemotherapy patients with breast cancer had a survival rate that is similar to those getting treatment after surgery. [67]

6.2. Radiation therapy

A type of therapy called ionizing radiation treatment is employed to treat cancer. Many times, it's called irradiation (RT, RTx, or XRT). Its goal is to eliminate cancerous cells or stop their proliferation.

Typically, a conventional particle accelerator is used to deliver it. For a lot of tumors that have only extent to one area of the body, chemotherapy or radiation is a good alternative for treatment. It may also be used as adjuvant treatment to stop a tumor from growing back after operation to remove an initial malignant tumor (such early-stage breast cancer).

Radioactivity treatment has been utilized previously, during, and after chemotherapy for sensitive cancers because it works well with the drug. Because radiation treatment may slow down cell proliferation, it is often utilized to treat malignant tumors. Ionizing radiation origins cellular death by terminating the DNA in malignant tissue. A range of exposure angles are used to aim shaped radiation beams toward the tumor, where they cross and create an absorption that is much greater than in the healthy tissue that surrounds it. By doing this, normal tissues—like skin or organs—are spared from the radiation that would normally have to penetrate them in order to treat the tumor

The lymph nodes that drain from the tumor may also be included in the radiation fields if there is a opportunity of subclinical malignant distribution or if the tumor is clinically or radioactively associated with lymph nodes.

Unlike radiology, which procedures radiation for medical imaging and analysis, radiation oncology is a field of treatment that uses prescription radioactivity. A radiation oncologist may suggest radiation treatment as a preventative measure or in an effort to treat cancer. It might similarly be used as a therapeutic treatment (when the treatment has persistence benefit and can be restorative) or palliative treatment (where a cure is not feasible and the objective is for local sickness management or characteristic alleviation).

Furthermore, the immunotherapy procedure, hormone therapy, surgery, chemotherapy, or a mix of the four are routinely used with radiation treatment. Treatment with radiation therapy is a feasible option for most common kinds of cancer. The generous, location, and phase of the tumor by way of the patient's general health will regulate the precise goal of the therapy, whether it be palliative, adjuvant, neoadjuvant therapeutic, or curative.TBI, or whole body contamination, is a radiation therapy used to get the body ready for a bone marrow remove. Additional kind of radiation treatment that reduces disclosure to vigorous tissue during processes to treat malignancies of the breast, prostate, and further organs is called brachytherapy, in which a harmful source is positioned within before near the region that needs to be treated. Radiation therapy is a useful therapeutic option for a number of non-cancerous illnesses, including pterygium, aural neuromas, pigmented villonodular joint inflammation, trigeminal neuralgia, and chronic thyroid eye disease. Additionally, it may be used to stop heterotopic ossification, vascular restenosis, and the formation of keloid scars. [68]

6.3. Chemotherapy

Medicines (sometimes referred to as "anticancer drugs") are used in chemo to treat cancer and destroy cancer cells. Chemotherapy may be injected into the skin, muscles, veins, or arteries. As a tablet, it may also be swallowed. These days, the term "chemotherapy" mostly encompasses cytotoxic chemicals that often target rapidly multiplying cells, as opposed to targeted therapy. Chemotherapy drugs may block cell division via a variety of mechanisms, including chromosomal segregation and DNA duplication.

Most chemotherapy therapies mark all promptly growing cells; they are not particular to cancer cells, even if approximately cancer cells are unable to fix DNA damage, typical cells can, and more cancer cells cannot. Chemotherapy thus has the risk of harming healthy tissue, especially the intestinal lining and other tissues that regenerate quickly. These cells often recover on their own after treatment. [69]

Sometimes drugs are provided in combination because their interactions work better together than they do independently. This is known as "combination chemotherapy" because most chemotherapy treatments are given in grouping. Subsequently chemotherapy affects every region of the body, it may have a broad variety of unfavorable consequences. Patients frequently suffer hair loss as a result of the cancer treatments they take, which also mark the cells in the shock roots. This strong drug may also result in tiredness, lethargy, and nausea, provisional on the patient. Treatment for roughly lymphomas and leukemias includes high-dose chemotherapy and whole body irradiation (TBI). This treatment destroys the bone marrow, which hinders the body's ability to repair itself and produce new blood cells. Bone marrow or marginal blood stem cell collection is done before the ablative phase of the treatment to allow "liberate" once the medicine is administered. Autologous steam cell planting is the term for this. [70]

6.4. Targeted therapies

Since its beginning in the late 1990s, focused on medical care has significantly improved the the future for several cancers and is still an active field of study. This is the application of drugs that are specifics to the abnormal the proteins seen in tumors cells. Targeted treatment treatments known as small molecule often operates as metabolic domain blocks on proteins that are mutated, over expressed, or otherwise crucial to the cancer cell. The tyrosine kinase inhibitors gefitinib (Iressa) and the drug (Gleevec/Glivec) are two notable examples another tactic is monoclonal antibody therapy, in which an antibody is used as the therapeutic agent and it attaches precisely to a protein proceeding the superficial of cancer cells. Illustrations include the anti-CD20 antibody rituximab, which is jumble-sale in a range of B-cell malignancies, and the anti-HER2 antibody trastuzumab (Herceptin), which is castoff in female breast cancer. Small peptides known as "homing devices" in attacked treatment may potentially attach to cell external receptors or the extracellular environment around the tumour. If radionuclide’s that are linked to these peptides (such RGDs) decay close to the cancer cell, the cancer cell will finally perish. These attachment motifs are particularly interesting as oligo- or multimers as they may increase tumor avidity and selectivity. A photosensitizer, skin oxygen, and light (frequently laser light) are the three sections of photodynamic therapy (PDT), a ternary cancer treatment. PDT is a viable therapy option for lung cancer and basal cell carcinoma (BCC). It can also be utilized to eliminate any remaining malignant tissue following the surgical excision of large tumors. Medical researchers revealed in February 2019 that iridium may bind to albumin to form a photosensitized protein that can enter cancer cells and, when exposed to light, destroy the tumor cells. High-energy therapeutic ultrasound has the impending to escalation the distribution of higher-density anti-cancer pharmaceutical load and Nano medicines to target cancer areas by a factor of 20 when compared to old-style mark cancer treatment. Embattled therapies are being developed in pre-clinical stages as prospective cancer managements. Examples comprise narcotics splice substituting oligonucleotides, which cause ERG exon hopping in prostate cancer models; multitargeted kinase inhibitors, which block PI3K along through other paths like MEK and PIM; and agents of NF-κB in treatment with chemotherapy confrontation representations. [71]

6.5. Immunotherapy

The term "cancer immunotherapy" encompasses a broad spectrum of treatment approaches intended to activate the patient's susceptible system beside the tumor. The routine of interferons and other cytokines to enhance an immune comeback in patients with melanoma and renal cell carcinoma, as fighting fit intravenous BCG immunotherapy for posturing bladder cancer, are examples of modern techniques for inducing an immune response against malignancies. A lot of investigation is currently being done on cancer vaccines to try to trigger specific immune responses against different types of cancer, such as deadly melanoma and renal cell carcinoma. Prostatic acid phosphatase peptides are loaded into the patient's dendritic cells as part of the Sipuleucel-T prostate cancer vaccination procedure. This sets off a specific immune response directed against cells derived from the prostate. In 2010, the FDA approved it.

Immunotherapy may be utilized in cases of genetically diverse donors used for allergic blood cell transplantation (typically from bone marrow), subsequently the donor's immune cells frequently target the tumor via an action called as the graft-versus-cancer consequence. As a result, allergic hematopoietic stem cell therapy (HSCT) has a higher rate of cancer cure than autologous transplantation, but HSCT also has more severe side effects. Since 1990, Japan has been a leader in the use of patient-derived NKs and T cells for cytotoxic cell-based immunotherapy. The main players that eradicate cancer cells at the earliest stage of their growth are NK cells and TCs. This therapy, known as autologous, is given in addition to conventional treatments including radiation, chemotherapy, or surgery.

Immune spot check therapy emphases on two immunological spot check proteins: cytotoxic T-lymphocyte connected protein 4 (CTLA-4) and involuntary cell death protein 1 (PD-1). After viruses have been eradicated, the invulnerable system employs spot check proteins as negative response mechanisms to assist the body in regaining balance.Cancer cells are able to take over this physiological regulating mechanism inside a tumor microenvironment, allowing them to "position a brake" on the susceptible system's answer to cancer and avoid immune monitoring.targeting their contributions to the development of immune spot check therapies targeting PD-1 and CTLA-4, Drs. James Allison of the University of Texas MD Anderson Cancer Centre in the United States and Tasuku Honjo of Kyoto University in Japan were awarded the 2018 Nobel Prize in Medicine. [72]

6.6 Hormonal therapy

A variety of cancers may be slowed down in development by blocking or providing certain hormones. Two typical examples of hormone-sensitive cancers are breast & prostate cancers. Obstructive estrogenic or testosterone is a critical supplementary treatment in many situations. Certain cancers may benefit from the use of progestogens, which are hormone agonists, as a therapeutic intervention. Patients undergoing hormone therapy may have a variety of symptoms, depending on the kind, including fatigue, nausea, and hot flashes. [73] Figure No. 4 depicts the hormone therapy used to treat cancer.

Fig.4: - Hormonal Therapy for Treatment of Cancer



6.7. Angiogenesis inhibitors

Angiogenesis inhibitors avoid angiogenesis, the huge enlargement of blood containers needed for tumors to spread and persist. A growing cell may metastasize, or spread to distant locations by invading surrounding tissues. Bevacizumab, axitinib, and cabozantinib are examples of angiogenesis inhibitors that have received several approvals.It is known that the flavonoids reduce VEGF and hypoxia-inducible factor (HIF) angiogenic activation, despite the fact that none of them have been evaluated in human clinical studies.[74]

6.8. Exercise prescription

Research demonstrating that exercise (as opposed to no exercise) is connected to enhanced death outcomes, fewer side effects from sequential cancer medicines, and reduced recurrence rates has led to a growing movement in the mainstream to employ prescription exercise as an adjuvant therapy for cancer. Even though there is a little chance of overuse injury if exercise is begun too soon, the benefits of enhanced cardiovascular and mental health exceed the dangers. Though it is indeterminate if superior results with implementation are connected to or contributing of cancer treatment, there is a significant benefit-risk ratio for include exercise in cancer therapy. Exercise physiologists and specialists in exercise medicine may assist primary care doctors and oncologists when it comes to recommending exercise to cancer patients. [75]

6.9. Synthetic lethality

When two or more genes express inadequately together, rather than when a single gene is defective, cell death occurs. We call this phenomena "synthetic lethality." Deficits may be caused by alterations, epigenetic modifications, or inhibition of one or both of the genetic material. Cancer cells usually lack a DNA restoration gene (also see Deficit in DNA Repair in Malignance.)

A mutation or, more often, epigenetic silencing might be the cause of this absence of DNA repair (see epigenetic quieting of DNA repair). Lump cells may be destroyed by synthetic lethality if the DNA repair absence is in one of the seven DNA repair routes (see DNA restoration pathways) as well as a compensation. [76]

6.10. Symptomatic management of cancer

While not officially recognized as a cancer therapy, managing cancer symptoms is essential for enhancing the quality of life for those who have the illness and for figuring out if they could benefit from further medicines. Doctors are generally experienced in managing discomfort, containing chemotherapy prompted nausea and vomiting, diarrhea, hemorrhaging and additional collective problems that plague cancer patients. A multidisciplinary domain known as relaxing care has developed in rejoinder to the needs of different patient crowds in terms of symptom management. Cancer pain may be concomitant with persistent tissue injury caused by the sickness or its therapies (e.g., radioactivity, chemotherapy, or surgery). While emotional issues and conservational factors may always underwrite to the emergence of pain behaviors, they are often not the primary causes of pain experienced by cancer patients. Even when patients with severe cancer-related pain are nearing the end of their life, palliative care should always be used to manage discomfort. Before the patient feels confident using the prescription medications required to control their symptoms, it may be important to address problems including the stigma attached to using opioids in society as well as health care usage.

In the past, physicians were hesitant to administer opioids to patients with terminal cancer due to the risk of addiction and decreased respiratory function. Preemptive pain management for cancer patients is now more widely acknowledged, largely because to the efforts of the mollifying care drive, a supplementary contemporary subset of the hospital drive. The World Health Organization established a "ladder" to provide medical staff members advice on how to manage cancer patients' pain after realizing that inadequately managed cancer pain was a global issue. One of the most prevalent symptoms of cancer is weariness, and several strategies have been developed to address it. [77-78]

6.11. Mental struggles/pain

One of the many difficulties that cancer patients encounter is mental turmoil. Patients through malignance may undergo from unhappiness as well as worry, overwhelm, and uncertainty. Chemotherapy is a very harsh medicine that destroys body cells. In addition to causing physical discomfort, these side effects emotionally exhaust patients and make them want to give up. For these and other reasons, hospitals provide a range of therapy alternatives and mental health treatments. Spiritual ideas, yoga, meditation, and therapy are a few of them. All of these are meant to relieve anxiety and give patients who may be feeling low hope.

6.12. Insomnia

Individuals who have had cancer treatment often have insomnia. Of cancer survivors, 60% or more suffer from insomnia. If ignored, insomnia may have longstanding effects on one's physical as well as physiological well-being. Sleeplessness is defined as a combination of difficulty falling or staying asleep and dissatisfaction with the quantity or quality of sleep. One's quality of life may be gravely lowered by sleep deprivation. It has been shown that cognitive behavioral therapy reduces depressive symptoms and insomnia in cancer survivors.

6.13. Muscle strength

Reduced muscle strength is one of the main side effects of many cancer treatments. So bodybuilding is quite essential, particularly in the first year after starting medicine. Studies have shown that practicing yoga, pilates, and water exercise may improve the general and mental health of those who have recovered from breast cancer.

6.14. Hospital care

Hospital assistance delivers comforting care at home or in a facility especially meant on behalf of this purpose for people with severe illnesses who are deemed terminal. Untreated cancer ultimately becomes deadly, and sometimes patients come to the conclusion that hospice care is better than treatment and all of its horrible side effects. Meeting the patient's practical, psychological, emotional, social, physical, and spiritual needs is the aim of hospice care. Advance care planning, or ACP, helps individuals who are nearing the end of their life make choices on their own medical care in the future. ACP helps people make decisions about their medical treatment and future goals, regardless of their current health status. It is best to discuss these options with family members or caregivers first. [79]

7. CHALLENGES AND CURRENT LIMITATIONS

Nanomedicine be present a very innovative and auspicious methodology to the development of new cancer therapies. The effectiveness of nanomedicine treatments in the in vivo and in vitro treatment of cancer has been shown in several research. However, only a very tiny percentage of nano carrier-based cancer treatments have been successful enough to advance to clinical trials. Therefore, resolving the challenges in developing therapeutically beneficial tailored Nano medical products is essential. [80]

7.1. Organoleptic characterization of nanomaterials

Arrangement, composition, dimension, surface characteristics, absorbency, charge, and accumulation activities are generally the primary physico-chemical characteristics of Nano carriers [140,141]. It is challenging to define Nano medicine products both before and after delivery due to variability within these features. The required qualitative attributes of the Nano-sized substances must be able to be monitored by quantitative analytical techniques. The measurement of a particle's heterogeneity in terms of mass, size, or form is called polydispersity (PD). It is crucial to the characterization of Nano carriers since minor changes in PD and physico-chemical properties can have a significant impact on secondary qualities including toxicity, in vivo results, and biocompatibility. [81-82] The Various nano material used in the characterization shown in figure no 5.

Fig.5: -Characterization Strategies of Nano-Materials



As a result, several techniques should be used to characterize Nano medicine products batch by batch. Most Nano medicine medications are prepared in aqueous buffers, which are ionic strength equivalent to physical pH. Nevertheless, interactions between Nano carriers and additional living fluids (like blood serum) or bio-molecules (like proteins) may cause particle agglomeration or aggregation. These interactions have the potential to drastically change how substances used in Nano medicine work in biological systems. As was previously said, complete characterization of Nano medicine products under settings that are therapeutically relevant is necessary. It is also difficult to characterize the stability and storage features (shelf-life) of goods containing Nano medicines. The creation of Nano medicines products has increased the usage of biodegradable nanomaterials like polymers. [83]

7.2. Safety concerns

Since nanoparticles are used so widely, toxicity concerns for the environment and human health must be addressed. Products used in Nano medicines have a nanoscale dimension with intracellular organelles and bio-molecules involved in cell signaling. Numerous investigations have shown evidence that nanoparticles might be connected to harmful biological interactions.

As a result, Nano toxicology is now a recognized area of study on its own. The amount of information about the toxicity of nanoparticles is growing**.**

However, comparing the toxicity of nanoparticles to that of macro materials is still challenging. The toxicity tests now employed for nanomaterials are identical to those employed for conventional medications. Therefore, it is important to promote the development of supplementary toxicity tests for Nano medicines substances as the current evaluation of nanoparticles toxicity may not be sufficient. The toxicity of nanomaterials is modulated by several variables. The behavior and effectiveness of Nano medicines medications at the nano-bio interface are influenced by properties including dimension, character, superficial area, surface charge, porosity, or hydrophobicity. Nano medicines products' complete toxicological characterization is hampered by the numerous factors involved. The most common causes of acute toxicity associated with Nano medicines substances include hemolysis, oxidative stress, complement activation, inflammation, and decreased mitochondrial function. Chronic toxicity analysis is more difficult, because most data are lacking**.**

By integrating cutting-edge or even predictive diagnostic techniques with innovative targeted tactics, risks in clinical development may be reduced. This allows for the identification of "safe-responders" and the realization of tailored cancer treatment. In this regard, the ranostic methods have enormous promise Environmental concerns have been raised in addition to medicinal ones.

Nanomaterials are being produced on a huge scale more and more in the chemical, cosmetic, and medicinal industries. As a result, it becomes more difficult but also more crucial to monitor exposure to nanoparticles in the workplace or environment and its effects. [85]

7.3. Regulatory issues

The European Medicines Agency (EMA) and FDA and have authorized numerous Nano medicine products on behalf of use in cancer therapy. They meet the current safety standards that these organizations have established. FDA, EMA, and other regulatory agencies, however, have not yet put explicit rules for pharmaceutical goods using nanomaterials into effect. A latest article described the FDA's strategy for regulating nanotechnology-related items. The FDA published "Considering Whether an FDA-Regulated Product Involves the Tender of Nanotechnology" as industry guidelines in June 2014. Caused materials with at least one dimension between one and one hundred nanometers are referred to as nanomaterials there. Materials with dimensions as small as 1 am are also included if they have the ability to produce nano-properties, or quantum effects. Regulatory choices about nano-medicine therapies are made based on an individual's evaluation of the advantages and dangers in the lack of data and guidelines. Nevertheless, this procedure takes a long time and might cause delays in the approval of Nano medicine products. Sustaining a high degree of proficiency in cutting-edge technology is necessary for effective regulationTo speed regulatory evaluation and thorough characterization of commodities related to Nano medicine, for example, the FDA work together with the Nanotechnology Characterization Laboratory (NCL). As part of the Prospect 2020 initiative, the European Technology Platform on Nano medicine (ETPN) expects to construct a European Nano-Characterization Laboratory (EU-NCL).

Controlling fears are important for the development of novel technologies to describe and track the quality of Nano medicine products, as well as for clinical trials and the endorsement procedure. Clear criteria are especially needed for the categorization and quality control of nano-similar, or generic versions of Nano medicine merchandises. The FDA approved Lipodox, the first generic liposomal merchandise, in 2013.In conclusion, it is still difficult for regulators to approve treatments including Nano medicine. It is anticipated that the emergence of Nano carriers created with more sophisticated and multipurpose instruments would even make the approval procedure more difficult. To give patients prompt access to cutting-edge medicines, regulatory bodies will need to improve and harmonize the standards for the approval of Nano medicine products. [8]

7.4. Manufacturing issues

The manufacture of Nano medicine products for commercialization presents significant technical challenges, with adherence to Good Manufacturing Practices (GMP) being a primary obstacle. Preclinical and early clinical research has often used a tiny quantity of nanomaterial. During large-scale manufacturing, the polydispersity of the nanomaterial may cause batch-to-batch variations in the chemical and physical properties. As a result, rigorous batch-to-batch control over the physico-chemical properties is required for the commercial manufacturing of The scarcity of Doxil® serves as an illustration of the difficulties involved in the development of Nano medicine treatments. November 2011 saw the suspension of Doxil® manufacture because of manufacturing and sterility problems. The subsequent Doxil® scarcity persisted until 2014 and led to patient treatments being postponed, prescription costs rising, and Doxil® being manufactured using a different method. Reproducibility and manufactured goods investigation are therefore essential elements for a large-scale, GMP-compliant manufacture of Nano medicine products.

For example, in order to prevent hydrolysis, typical bioconjugation procedures like maleimide or succinimide processes happen at a relatively slight pH range. Advanced pH-responsive Nano medicine compounds need maintaining the pH interval throughout the whole production process. The great cost of the fresh materials and the need for a time-consuming, multi-step manufacture development make the creation of Nano medicine treatments expensive. For example, the cost of manufacturing commercially available Nano-sized drugs such as Abraxane® and Doxil® is far higher than that of manufacturing their free-drug equivalents, doxorubicin and paclitaxel. This may dissuade pharmaceutical corporations from mass-producing Nano carriers. Therefore, the clinical benefit must be significant to balance the costs of development and production and to justify the higher pricing for Nano medicine drugs as compared to standard therapy. [87-88]

8. CONCLUSION

To sum up, the development of tailored medication delivery systems is an significant development in the ongoing fight compared to malignance. These technologies have the potential to completely transform cancer therapy by lowering side effects and increasing efficacy by directly targeting cancer cells while causing the least amount of harm to healthy organs. This study highlights the significant impact tailored medication delivery systems may have on enhancing patient outcomes and quality of life via careful examination of various delivery methods, limits, recent breakthroughs, and future possibilities. As this area of study develops, it is critical to give priority to further research and creativity in order to eventually convert these discoveries into real advantages for cancer patients all around the world. With concerted efforts and continued interdisciplinary collaboration, directed drug delivery systems hold promise for reshaping the landscape of malignance therapy, accompanying in a new era of modified and precision medicine.

Nanotechnology has marshaled in a promising novel frontier in cancer treatment, offering a versatile platform for the supply of small particles crucial for cancer recognition, identification, and therapy. Nano-particle (NP)-based drug delivery systems have demonstrated remarkable rewards over conservative drugs, containing improved pharmacokinetics, tumor targeting, and stability, along with the potential for combination therapy to overcome multidrug resistance. Various categories of NPs, such as polymeric, metallic, and hybrid NPs, have displayed enhanced effectiveness in drug delivery, signaling a shift toward personalized and precision medicine in cancer treatment. Despite these advancements, challenges remain, excluding the lack of in vitro models that accurately mimic in vivo conditions, as well as concerns about immunotoxicity, long-term toxicity, and neurotoxicity associated with NP-based therapies. While "Nano vaccines" and "artificial antigen-presenting cells have demonstrated enhanced efficacy in immunotherapy, their clinical translation still requires thorough examination of safety and tolerability. Looking ahead, further research into the mechanisms underlying cancer, multidrug resistance, and the exchanges among NPs and biological systems will be essential for the rational design of Nano therapeutics. As the field come to an end to develop, it is anticipated that more NP-based drugs will emerge for clinical use, leveraging insights from proteomics research and advancements in nanotechnology. By gaining a deeper understanding of the intricacies of NP-based drug delivery, including factors such as the enhanced permeability and retention (EPR) consequence and passive targeting mechanisms, we can unlock the full potential of nanotechnology in malignance therapy.

In summary, while the clinical conversion of NP-based malignance therapy is quiet in its early stages, the convergence of nanotechnology and cancer therapy development holds great promise for revolutionizing cancer treatment. With continued innovation and interdisciplinary collaboration, we are poised to overwhelmed current experiments and harness the transformative power of nanotechnology in the fight against malignance.

ACKNOWLEDGEMENT

The authors are also grateful to the Department of Science and Technology (DST-FIST) Letter no-SR/FST/COLLEGE/2018/418, New Delhi for providing financial assistance.

DECLARATION OF INTEREST

The Authors declared no conflict of interest in this review article.

REFERENCES

[1] Heister E, Neves V, Tîlmaciu C, Lipert K, Beltrán VS, Coley H, Silva SR, McFadden J. Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy. *Carbon.* 2009;47:2152–2160.

[2] Jamieson T, Bakhshi R, Petrova D, Pocock R, Imani M, Seifalian AM. Biological applications of quantum dots. *Biomaterials.* 2007;28(31):4717–4732.

[3] Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, Farokhzad OC. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. *Nano Lett.* 2007;7(10):3065–3070.

[4] Xu ZP, Zeng QH, Lu GQ, Yu AB. Inorganic nanoparticles as carriers for efficient cellular delivery. *Chem Eng Sci.* 2006;61(3):1027–1040.

[5] Zhao X, Hilliard LR, Mechery SJ, Wang Y, Bagwe RP, Jin S, Tan W. A rapid bioassay for single bacterial cell quantitation using bioconjugated nanoparticles. *Proc Natl Acad Sci USA.* 2004;101(42):15027–15032.

[6] Mousa SA, Bharali DJ. Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications. *Cancers.* 2011;3(3):2888–2903.

[7] Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. Treating metastatic cancer with nanotechnology. *Nat Rev Cancer.* 2011;12(1):39–50.

[8] Castaneda RT, Khurana A, Khan R, Daldrup-Link HE. Labeling stem cells with ferumoxytol, an FDA-approved iron oxide nanoparticle. *J Vis Exp JoVE.* 2011;57:e3482.

[9] Basoglu H, Goncu B, Akbas F. Magnetic nanoparticle-mediated gene therapy to induce Fas apoptosis pathway in breast cancer. *Cancer Gene Ther.* 2018;25(5–6):141–147.

[10] Meng J, Fan J, Galiana G, Branca R, Clasen P, Ma S, Soboyejo W. LHRH-functionalized superparamagnetic iron oxide nanoparticles for breast cancer targeting and contrast enhancement in MRI. *Mater Sci Eng C.* 2009;29(4):1467–1479.

[11] Legge CJ, Colley HE, Lawson MA, Rawlings AE. Targeted magnetic nanoparticle hyperthermia for the treatment of oral cancer. *J Oral Pathol Med.* 2019;48(9):803–809.

[12] Maurya A, Singh AK, Mishra G, Kumari K, Rai A, Sharma B, Kulkarni GT, Awasthi R. Strategic use of nanotechnology in drug targeting and its consequences on human health: a focused review. *Interv Med Appl Sci.* 2019;11(1):38–54.

[13] Khosravi-Darani K, Mozafari MR, Rashidi L, Mohammadi M. Calcium based non-viral gene delivery: an overview of methodology and applications. *Acta Med Iran.* 2010;48(3):133–141.

[14] Mozafari MR, Reed CJ, Rostron C, Kocum C, Piskin E. Construction of stable anionic liposome-plasmid particles using the heating method: a preliminary investigation. *Cell Mol Biol Lett.* 2002;7(3):923–927.

[15] Mozafari MR, Reed CJ, Rostron C. Cytotoxicity evaluation of anionic nanoliposomes and nanolipoplexes prepared by the heating method without employing volatile solvents and detergents. *Pharmazie.* 2007;62(3):205–209

[16] Katragadda C, Choudhury P, Murthy P (2021) Nanoparticles as non-viral gene delivery vectors.

[17] Kneuer C, Sameti M, Bakowsky U, Schiestel T, Schirra H, Schmidt H, Lehr CM. A nonviral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro. *Bioconjug Chem.* 2000;11(6):926–932.

[18] Gary-Bobo M, Hocine O, Brevet D, Maynadier M, Raehm L, Richeter S, Charasson V, Loock B, Morère A, Maillard P, Garcia M, Durand JO. Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. *Int J Pharm.* 2012;423(2):509–515.

[19] Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: an overview. *Cancers.* 2014;6(3):1769–1792.

[20] Schneider E, Hunke S. ATP-binding-cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains. *FEMS Microbiol Rev.* 1998;22(1):1–20.

[21] Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. *Can Res.* 2000;60(20):5761–5766

[22] Singh JP, Mittal MK, Saxena S, Bansal A, Bhatia A, Kulshreshtha P Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer—a prospective clinical study. World J Surg Oncol . 2005;3:61. 10.1186/1477-7819-3-61

[23] Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. *Nat Rev Cancer.* 2003;3(7):502–516

[24] Murakami M, Cabral H, Matsumoto Y, Wu S, Kano MR, Yamori T, Nishiyama N, Kataoka K Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med 2011;3(64):64ra2.

[25] 126. Yu B, Song N, Hu H, Chen G, Shen Y, Cong H. A degradable triple temperature-, pH-, and redox-responsive drug system for cancer chemotherapy. *J Biomed Mater Res Part A.* 2018;106(12):3203–3210. doi: 10.1002/jbm.a.36515.

[26] Kundu M, Sadhukhan P, Ghosh N, Chatterjee S, Manna P, Das J, Sil PC. pH-responsive and targeted delivery of curcumin via phenylboronic acid-functionalized ZnO nanoparticles for breast cancer therapy. *J Adv Res.* 2019;18:161–172. doi: 10.1016/j.jare.2019.02.036.

[27] Cuvier C, Roblot-Treupel L, Millot JM, Lizard G, Chevillard S, Manfait M, Couvreur P, Poupon MF. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. *Biochem Pharmacol.* 1992;44(3):509–517. doi: 10.1016/0006-2952(92)90443-m.

[28] Soma CE, Dubernet C, Bentolila D, Benita S, Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. *Biomaterials.* 2000;21(1):1–7. doi: 10.1016/s0142-9612(99)00125-8.

[29] Zhang S, Guo N, Wan G, Zhang T, Li C, Wang Y, Wang Y, Liu Y. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer. *J Nanobiotechnol.* 2019; 17(1):109. doi: 10.1186/s12951-019-0540-9.

[30] He J, Gong C, Qin J, Li M, Huang S. Cancer cell membrane decorated silica nanoparticle loaded with miR495 and doxorubicin to overcome drug resistance for effective lung cancer therapy. *Nanoscale Res Lett.* 2019; 14(1):339. doi: 10.1186/s11671-019-3143-3.

[31] Viktorsson K, Lewensohn R, Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. *Adv Cancer Res.* 2005; 94:143–196. doi: 10.1016/S0065-230X(05)94004-9.

[32] Choi KY, Correa S, Min J, Li J, Roy S, Laccetti KH, Dreaden E, Kong S, Heo R, Roh YH, Lawson EC, Palmer PA, Hammond PT. Binary targeting of siRNA to hematologic cancer cells *in vivo* using layer-by-layer nanoparticles. *Adv Funct Mater*. 2019; 29(20):1900018. doi: 10.1002/adfm.201900018

[33] Fan L, Li F, Zhang H, Wang Y, Cheng C, Li X, Gu CH, Yang Q, Wu H, Zhang S. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. *Biomaterials.* 2010; 31(21):5634–5642.

[34] Zhao MD, Li JQ, Chen FY, Dong W, Wen LJ, Fei WD, Zhang X, Yang PL, Zhang XM, Zheng CH. Co-delivery of curcumin and paclitaxel by "core-shell" targeting amphiphilic copolymer to reverse resistance in the treatment of ovarian cancer. *Int J Nanomed.* 2019;14:9453–9467. doi: 10.2147/IJN.S224579

[35] Van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. *AAPS J*. 2010; 12(2):171–180. doi: 10.1208/s12248-010-9174-4.

[36] Khiste SK, Liu Z, Roy KR, Uddin MB, Hosain SB, Gu X, Nazzal S, Hill RA, Liu YY. Ceramide-rubusoside nanomicelles, a potential therapeutic approach to target cancers carrying p53 missense mutations. *Mol Cancer Ther.* 2020; 19(2):564–574. doi: 10.1158/1535-7163.MCT-19-0366.

[37] Choi SH, Jin SE, Lee MK, Lim SJ, Park JS, Kim BG, Ahn WS, Kim CK, Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur J Pharm Biopharm. 2008; 68(3):545–554. 10.1016/j.ejpb.2007.07.011.

[38] Prabha S, Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. *Mol Pharm.* 2004; 1(3):211–219. doi: 10.1021/mp049970.

[39] Cheng H, Wu Z, Wu C, et al Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA cationic polyester in liver cancer cells. Mater Sci Eng C Mater Biol Appl. 2018: 83:210–217. 10.1016/j.msec.2017.08.075

[40] Zhao Y, Huan ML, Liu M, Cheng Y, Sun Y, Cui H, Liu DZ, Mei QB, Zhou SY. Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance. *Sci Rep*. 2016;6:35267. doi: 10.1038/srep35267.

[41] Singh SK, Lillard JW, Jr, Singh R. Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer. *Cancer Lett.* 2018;427:49–62. doi: 10.1016/j.canlet.2018.04.017.

[42] Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, Shu Y. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. *Mol Cancer*. 2019; 18(1):157. doi: 10.1186/s12943-019-1089-9.

[43] Luo B, Li W, Wang R, et al (2017) Effect of hypoxia on expression of multidrug resistance protein 2 and its regulation mechanism. J Cent South Univ Med Sci 42(1):98–107. 10.11817/j.issn

[44] Hajizadeh F, Moghadaszadeh Ardebili S, Baghi Moornani M, Masjedi A, Atyabi F, Kiani M, Namdar A, Karpisheh V, Izadi S, Baradaran B, Azizi G, Ghalamfarsa G, Sabz G, Yousefi M, Jadidi-Niaragh F. Silencing of HIF-1α/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. *Eur J Pharmacol.* 2020;882:173235. doi: 10.1016/j.ejphar.2020.173235.

[45] Zhang J, Zhang Q, Lou Y, Fu Q, Chen Q, Wei T, Yang J, Tang J, Wang J, Chen Y, Zhang X, Zhang J, Bai X, Liang T (2018) Hypoxia-inducible factor-1α/interleukin-1β signaling enhances hepatoma

epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment. Hepatology (Baltimore, Md.) 67(5):1872–1889. 10.1002/hep.29681.

[46] Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. *Drug Discov Today.* 2007;12 (19–20):853–859. doi: 10.1016/j.drudis.2007.08.006.

[47] Long Q, Lin TY, Huang Y, Li X, Ma AH, Zhang H, Carney R, Airhart S, Lam KS, deVere White RW, Pan CX, Li Y. Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. *Nanomed Nanotechnol Biol Med.* 2018;14(3):789–799. doi: 10.1016/j.nano.2017.12.014.

[48] Sebak AA, Gomaa I, ElMeshad AN, Farag MH, Breitinger U, Breitinger HG, AbdelKader MH. Distinct proteins in protein corona of nanoparticles represent a promising venue for endogenous targeting—part i: in vitro release and intracellular uptake perspective. *Int J Nanomed.* 2020;15:8845–8862. doi: 10.2147/IJN.S273713. Vroman L, Adams AL, Fischer GC, Munoz PC. Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. *Blood.* 1980;55(1):156–159. doi: 10.1182/blood.V55.1.156.156.

[49] Pederzoli F, Tosi G, Vandelli MA, Belletti D, Forni F, Ruozi B (2017) Protein corona and nanoparticles: How can we investigate on? Retrieved July 30, 2021, from 10.1002/wnan.1467 [

[50] Risha Y, Minic Z, Ghobadloo SM, Berezovski MV. The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers. *Sci Rep.* 2020;10(1):13572. doi: 10.1038/s41598-020-70393-4.

[51] Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. *Biotechnol J.* 2011;6(9):1130–1146. doi: 10.1002/biot.201100054.

[52] Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Durieux B, Röder N, Löffler K, Lange C, Fechtner M, Möpert K, Fisch G, Dames S, Arnold W, Jochims K, Giese K, Wiedenmann B, Kaufmann J. Atu, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. *Can Res.* 2008;68(23):9788–9798. doi: 10.1158/0008-5472.CAN-08-2428.

[53] Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. *Nat Cell Biol.* 2009;11(3):228–234. doi: 10.1038/ncb0309-228.

[54] Kato RB, Roy B, De Oliveira FS, Ferraz EP, De Oliveira PT, Kemper AG, Hassan MQ, Rosa AL, Beloti MM. Nanotopography directs mesenchymal stem cells to osteoblast lineage through regulation of microRNA-SMAD-BMP-2 circuit. *J Cell Physiol.* 2014;229(11):1690–1696. doi: 10.1002/jcp.24614.

[55] Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. *Pharm Res.* 2016;33(10):2373–2387. doi: 10.1007/s11095-016-1958-5.

[56] Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. *P & T.* 2017;42(12):742–755.

[57] Rezvantalab S, Drude NI, Moraveji MK, Güvener N, Koons EK, Shi Y, Kiessling F. PLGA-based nanoparticles in cancer treatment. *Front Pharmacol.* 2018;9:1260. doi: 10.3389/fphar.2018.01260.

[58] Yona S, Gordon S. From the reticuloendothelial to mononuclear phagocyte system—the unaccounted years. *Front Immunol.* 2015;6:328. doi: 10.3389/fimmu.2015.00328.

[59] Liang T, Zhang R, Liu X, Ding Q, Wu S, Li C, Lin Y, Ye Y, Zhong Z, Zhou M. Recent Advances in Macrophage-Mediated Drug Delivery Systems. *Int J Nanomed.* 2021;16:2703–2714. doi: 10.2147/IJN.S298159.

[60] Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. *Clin Transl Med.* 2017;6(1):44. doi: 10.1186/s40169-017-0175-0.

[61] Hu Y, Gaillard PJ, de Lange E, Hammarlund-Udenaes M (2019) Targeted brain delivery of methotrexate by glutathione PEGylated liposomes: How can the formulation make a difference? Eur J Pharm Biopharm 139:197–204. 10.1016/j.ejpb.2019.04.004

[62] Feng Q, Shen Y, Fu Y, Muroski ME, Zhang P, Wang Q, Xu C, Lesniak MS, Li G, Cheng Y. Self-assembly of gold nanoparticles shows microenvironment-mediated dynamic switching and enhanced brain tumor targeting. *Theranostics.* 2017;7(7):1875–1889. doi: 10.7150/thno.18985.

[63] Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. *Adv Drug Deliv Rev.* 2011;63(6):456–469. doi: 10.1016/j.addr.2011.02.001.

[64] Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. *Adv Drug Deliv Rev.* 2002;54(5):631–651. doi: 10.1016/s0169-409x(02)00044-3.

[65] Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. *Pharm Res.* 1996;13(12):1838–1845. doi: 10.1023/a:1016085108889.

[66] Zang X, Zhao X, Hu H, Qiao M, Deng Y, Chen D (2017) Nanoparticles for tumor immunotherapy. Eur J Pharm Biopharm 115:243–256. 10.1016/j.ejpb.2017.03.013

[67] Quazi S (2021) An overview of CAR T cell mediated B cell maturation antigen therapy. Preprints 2021, 2021090212. 10.20944/preprints202109.0212.v1

[68] Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108:479e485.

[69] Siegel RL, Miller KD, Jemal A, Cancer statistics. 2016, CA Cancer J Clin. 2016;66: 7e30.

[70] Schottenfeld D, Fraumeni Jr JF. Cancer Epidemiology and Prevention. Oxford University Press; 2006.

[71] Yoo KY, Shin HR. Cancer epidemiology and prevention. Korean J Epidemiol. 2003;25:1e15.

[72] Aizawa K, Liu C, Tang S, et al. Tobacco carcinogen induces both lung cancer and non-alcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be attenuated by lycopene supplementation. Int J Cancer. 2016;139: 1171-1181.

[73] Poon SL, McPherson JR, Tan P, Teh BT, Rozen SG. Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention. Genome Med. 2014;6:24.

[74] Trafialek J, Kolanowski W. Dietary exposure to meat-related carcinogenic substances: is there a way to estimate the risk? Int J Food Sci Nutr. 2014; 65: 774-780.

[75] Cumberbatch MG, Cox A, Teare D, Catto JW. Contemporary occupational carcinogen exposure and bladder cancer: a systematic review and Metaanalysis. JAMA Oncol. 2015;1:1282-1290.

[76] Antwi SO, Eckert EC, Sabaque CV, et al. Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer. Cancer Causes Control. 2015; 26:1583-1591.

[77] Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118:3030-3044.

[78] Seto M, Honma K, Nakagawa M. Diversity of genome profiles in malignant lymphoma. Cancer Sci. 2010;101:573-578.

[79] Cigudosa JC, Parsa NZ, Louie DC, et al. Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes, Chromosomes Cancer. 1999;25:123-133.

[80] Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550-554.

[81] Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S. Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J. 1984;3:3257.

[82] Wei Q, Li L, Chen D. DNA Repair, Genetic Instability, and Cancer: World Scientific. 2007.

[83] Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science. 2001; 291:1284-1289.

[84] Alvarez-Buylla ER, Chaos A, Aldana M, et al. Floral morphogenesis: stochastic explorations of a gene network epigenetic landscape. PLoS One. 2008; 3:3626.

[85] Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057-1068.

[86] D.D. Lasic , Liposomes in gene delivery , CRC press, boca Raton, FL,1997.

[87] Allen T.M. , Cullis P.R, Liposomal drug Delivery system : from the concept to clinical applications, Adv. Drug Deliv. 2013;65(1): 36-48.

[88] Hans M., Lowman A., Biodegradable nanoparticles for drug delivery and targeting, Curr. Opin. Solid State Mater.Sci ; 2002; 6(4); 319-327.

Citation: Piyush Tiwari, Mahendra Kumar Sahu, Rahul Kumar, Swapnil Lal, Shailendra Kumar Sharma, Current Progress in Therapies and Future Directions on The Development of Novel Drug Delivery System for Enhanced Cancer Treatment, International Journal of Medical Sciences (IJMS), 2(2), 2024, pp. 1-24

Abstract: https://iaeme.com/Home/article_id/IJMS_02_02_001

Article Link:
https://iaeme.com/MasterAdmin/Journal_uploads/IJMS/VOLUME_2_ISSUE_2/IJMS_02_02_001.pdf

✉ **editor@iaeme.com**